Balazs Halmos, MD, MS
Dr. Balazs Halmos is the Director of Thoracic Oncology, Director of Clinical Cancer Genomics, and Associate Director of Clinical Science at Montefiore Einstein Comprehensive Cancer Center. As one of three team leaders of the center’s lung cancer team, his clinical focus is on the management of patients with thoracic malignancies, including malignant pleural mesothelioma and esophageal cancer. He is a proponent of personalized cancer medicine and is working to develop a molecular testing paradigm for the Montefiore Health System to facilitate the best patient outcomes possible.[1]
Education and Career
Dr. Halmos attended medical school at Semmelweis University in Budapest, Hungary, and graduated summa cum laude. He completed an internship and residency in Internal Medicine at St. Luke’s-Roosevelt Hospital/Columbia University in New York City, then moved on to Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, Massachusetts where he completed a fellowship in Hematology/Oncology while simultaneously earning an MS degree in Clinical Sciences from Harvard Medical School.
Following the completion of his education, Dr. Halmos has served as a faculty member at Harvard Medical School and at Case Western Reserve University. Before joining Montefiore Einstein Comprehensive Cancer Center, he was the Director of Thoracic Medical Oncology at Columbia University Medical Center, as well as Associate Professor of Medicine and Chairman of the Cancer IRB.[1]
Board certified in both Internal Medicine and Medical Oncology, Dr. Halmos is a permanent review board member for the American Cancer Society. He is also the recipient of multiple awards from respected medical professional organizations, including the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Cancer Society.
Research
Dr. Halmos is focused on studying targeted agents for the treatment of thoracic malignancies. He is working on translational studies of different aspects of lung cancer biology including oncogenic tyrosine kinase targeting and resistance to traditional cancer protocols such as chemotherapy and radiation therapy, as well as more recent innovations including targeted therapeutics. He is currently overseeing the thoracic clinical trials program of novel clinical studies at Montefiore Einstein Comprehensive Cancer Center.[1]
